This session will highlight the mechanisms of action, pathways, and rationale for using immunotherapy to treat GI malignancies, assess guideline recommendations for biomarker testing to guide treatment selection across tumor types, evaluate the clinical profiles of current and emerging therapies designed to inhibit the deleterious effects of these diseases, evaluate safety and efficacy data reported to date, and assess potential clinical applications.
Safety and Antitumor Activity of Pembrolizumab in Patients with Advanced Microsatellite Instability–High (MSI-H) Colorectal Cancer: KEYNOTE-164 Dung Le, et al., O-021
